Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

BMC Neurology

Table 2 Change from baseline to 6 months for TSQM Effectiveness, Side Effects and Convenience subscale scores

	GA to fingolimod	Remaining on GA	IM IFN beta-1a to fingolimod	Remaining on IM IFN beta-1a	SC IFN beta-1a to fingolimod	Remaining on SC IFN beta-1a	IFN beta-1b to fingolimod	Remaining on IFN beta-1b
	(n = 262)	(n = 74)	(n = 205)	(n = 48)	(n = 196)	(n = 58)	(n = 125)	(n = 39)
Effectiveness	12.16 ± 1.49	0.62 ± 2.76	13.31 ± 1.48	1.37 ± 3.13	15.07 ± 1.65	1.62 ± 3.02	17.59 ± 2.06	0.68 ± 3.62
Side effects	9.25 ± 1.41	4.47 ± 2.64	30.62 ± 1.56	6.56 ± 3.27	27.83 ± 1.43	-0.42 ± 2.61	21.50 ± 1.88	-1.24 ± 3.30
Convenience	38.01 ± 0.80	3.11 ± 1.49	43.83 ± 0.94	5.70 ± 1.97	42.36 ± 1.02	1.66 ± 1.87	41.57 ± 1.15	1.31 ± 2.04

Values are displayed as least-squares means ± standard errors. p <0.001 for all comparisons; italics = non-significant result.
GA, glatiramer acetate; IFN, interferon; IM, intramuscular; SC, subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.